Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Not involved in this article.	n/a

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Not involved in this article.	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Not involved in this article.	n/a

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Not involved in this article.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	Not involved in this article.	n/a
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	Not involved in this article.	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Not involved in this article.	n/a
Microbes: provide species and strain, unique accession number if available, and source	Not involved in this article.	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes, Methods/ Patients and samples/paragraph 1	
Provide statement confirming informed consent obtained from study participants.	Yes, Methods/ Patients and samples/paragraph 1	
Report on age and sex for all study participants.	Yes, Methods/ Patients and samples/paragraph 2	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Not involved in this article.	n/a

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Yes, Methods/Protein extraction and identification/paragraph 1-5	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	Yes, Methods/Patients and samples/ paragraph 2	
Randomisation	Not involved in this article.	n/a
Blinding	Not indicated in this article	n/a
Inclusion/exclusion criteria	Yes, Methods/Patients and samples/ paragraph 3	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Not indicated in this article	n/a
Define whether data describe technical or biological replicates	Not indicated in this article	n/a

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes, Methods/Patients and samples/ paragraph 1	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Not involved in this article.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Not involved in this article.	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	Not involved in this article.	n/a

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Yes, Methods/Peptide identification and quantification/paragraph 1; Bioinformatics Analyses/paragraph 1	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Yes, Methods/Statistical Analysis/paragraph 1	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	No publicly available data are reused.	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	No publicly available data are reused.	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	No publicly available data are reused.	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Yes, Methods/ Protein extraction and identification/paragraph 1-5; software were included in this research.	
If code is publicly available, provide accession number in repository, or DOI or URL.	No publicly available data are reused.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/tp-21-559